Preliminary Study of Buprenorphine and Bupropion for Opioid Dependent Smokers
Abstract
In this double-blind, placebo-controlled trial, bupropion (BUPRO, 300 mg/day) was compared to placebo (PBO) for concurrent treatment of
opioid and tobacco addiction in 40
opioid-dependent smokers stabilized on buprenorphine (BUPRE, 24 mg/day). Participants received contingent, monetary reinforcement for abstinence from smoking, illicit opioids, and cocaine.